As of Friday close, CTI BioPharma Corp.’s (NASDAQ:CTIC) stock was down -$0.07, moving down -1.59 percent to $4.34. The average number of shares traded per day over the past five days has been 4,034,500 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.11 fall in that time frame. In the last twenty days, the average volume was 3,870,510, while in the previous 50 days, it was 3,123,408.
Since last month, CTIC stock retreated -18.42%. Shares of the company fell to $4.20 on 03/17/23, the lowest level in the past month. A 52-week high of $7.80 was reached on 01/03/23 after having rallying from a 52-week low of $3.32. Since the beginning of this year, CTIC’s stock price has dropped by -27.79% or -$1.67, and marked a new high 1 time. However, the stock has declined by -44.36% since its 52-week high.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
CTIC stock investors should be aware that CTI BioPharma Corp. (CTIC) stock had its last reported insider trading activity 53 days ago on Jan 24. Fong James K, the EVP & Chief Commercial Officer of the company, disposed of 100,000 shares for $6.00 on Jan 24. It resulted in a $600,000 divestment by the insider. Craig Adam R sold 85,317 shares at an average price of $6.00 on Jan 24. The insider now owns 29,440 shares following the transaction. On Jan 03, President and CEO Craig Adam R sold 84,683 shares at $6.01 apiece. The transaction was valued at $509,224.
In the three months ended September 29, CTI BioPharma Corp.’s quick ratio stood at 1.20, while its current ratio was 1.20, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 93.50% percent. Based on annual data, CTIC earned $50.43 million in gross profit and brought in $53.95 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -87.30%. Return on equity (ROE) for the past 12 months was 550.20%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. CTIC’s revenue rose 100.0% to $18.24 million during the quarter, while net income inched up to $21.08 million. While analysts expected CTI BioPharma Corp. to report -$0.16 quarterly earnings, the actual figure was -$0.13 per share, beating the consensus estimate by 18.80%. During the quarter, the company generated -$13.06 million in EBITDA. The liabilities of CTI BioPharma Corp. were 143.5 million at the end of its most recent quarter ended September 29, and its total debt was $109.53 million. The value of shareholders’ equity is $131.84 million.
This quick technical analysis looks at CTI BioPharma Corp.’s (CTIC) price momentum. With a historical volatility rate of 49.15%, the RSI 9-day stood at 18.80% on 17 March.
With respect to its five-day moving average, the current CTI BioPharma Corp. price is down by -2.47% percent or -$0.11. At present, CTIC shares trade -18.42% below its 20-day simple moving average and -2.47% percent below its 100-day simple moving average. However, the stock is currently trading approximately -19.03% below its SMA50 and -20.07% below its SMA200.
Stochastic coefficient K was 9.02% and Stochastic coefficient D was 10.59%, while ATR was 0.23. Given the Stochastic reading of 10.37% for the 14-day period, the RSI (14) reading has been calculated as 24.10%. As of today, the MACD Oscillator reading stands at -0.13, while the 14-day reading stands at -0.41.
SVB Leerink launched its rating on CTI BioPharma Corp. (NASDAQ: CTIC) to an Outperform in a note to investors on October 17, 2022. CTI BioPharma Corp. (CTIC) has been rated Buy by analysts. According to 0 brokerage firms, CTIC is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate CTI BioPharma Corp. stock as buy, with 9 recommending it as overweight.
With a median target price of $10.00, the current consensus forecast for the stock is $8.10 – $15.00. Based on these forecasts, analysts predict CTI BioPharma Corp. (CTIC) will achieve an average price target of $11.23.